Hepatitis B Virus in Polish Blood Donors in the Period 2005–2019—Significant Changes in Epidemiology and Demographic Characteristics of Infected Donors

In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994–1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000–2011, all 14-year-o...

Full description

Saved in:
Bibliographic Details
Published inViruses Vol. 17; no. 1; p. 60
Main Authors Kopacz, Aneta, Kubicka-Russel, Dorota, Liszewski, Grzegorz, Sulkowska, Ewa, Chrzanowska, Anna, Zwolińska, Paulina, Noceń, Ewa, Potępa, Anna, Łętowska, Magdalena, Grabarczyk, Piotr
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.01.2025
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994–1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000–2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman’s coefficient R = −0.98 and R = −0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = −0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21–50 years than in donors ≤20 years, most often in the 41–50 age group. The frequency of OBI increased with donor age and was the highest in the 51–60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.
AbstractList In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994–1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000–2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman’s coefficient R = −0.98 and R = −0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = −0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21–50 years than in donors ≤20 years, most often in the 41–50 age group. The frequency of OBI increased with donor age and was the highest in the 51–60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994-1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000-2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman's coefficient R = -0.98 and R = -0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = -0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21-50 years than in donors ≤20 years, most often in the 41-50 age group. The frequency of OBI increased with donor age and was the highest in the 51-60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994-1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000-2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman's coefficient R = -0.98 and R = -0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = -0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21-50 years than in donors ≤20 years, most often in the 41-50 age group. The frequency of OBI increased with donor age and was the highest in the 51-60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10 5 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994–1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000–2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly ( p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently ( p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman’s coefficient R = −0.98 and R = −0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = −0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21–50 years than in donors ≤20 years, most often in the 41–50 age group. The frequency of OBI increased with donor age and was the highest in the 51–60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10[sup.5] inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994–1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000–2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly (p = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently (p < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman’s coefficient R = −0.98 and R = −0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = −0.54, p < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21–50 years than in donors ≤20 years, most often in the 41–50 age group. The frequency of OBI increased with donor age and was the highest in the 51–60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994-1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000-2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA. Based on the data from the Blood Transfusion Centers, changes in HBV detection in Polish blood donors were analyzed, starting from the introduction of mandatory NAT screening until 2019. During the period under analysis, a total of 11,625 HBV-infected donors were identified: 97.95% were seropositive (confirmed HBsAg) and 2.05% were seronegative (NAT yields). The detection frequency for both categories of infections was significantly ( = 0.05) higher for men than for women (Residual Risk RR = 1.4 and RR = 2.63, respectively). Seropositive infections were detected more frequently ( < 0.05) in first-time donors than in repeat donors (RR = 360), while no significant differences were observed in the category of seronegative infections. A downward trend in HBsAg detection was observed in both first-time and repeat donors (Spearman's coefficient R = -0.98 and R = -0.90, respectively). The frequency of HBsAg in first-time donors decreased 5-fold, and, in repeat donors, 30-fold. In both subpopulations, the largest decrease occurred in the age group ≤ 20 years (i.e., donors born between 1985 and 2001). The incidence of window period (WP) infections in the repeat donor group demonstrated a downward trend (R = -0.54, < 0.05), and in the first-time donor group, no significant trend was recorded. For occult hepatitis B infection (OBI), no significant trend was observed in either donor subpopulation. WP infections were detected significantly more often in donors aged 21-50 years than in donors ≤20 years, most often in the 41-50 age group. The frequency of OBI increased with donor age and was the highest in the 51-60 age group. A spectacular decrease in the frequency of HBsAg(+) infections was observed in current study, indicating the effectiveness of the hepatitis prevention strategy applied in Poland. We expect that the improvement in the epidemiological situation among blood donors causes a reduction in the risk of TT-HBV. Confirmation of this hypothesis by the analysis of residual risk should be a subject of further studies.
Audience Academic
Author Potępa, Anna
Grabarczyk, Piotr
Kopacz, Aneta
Liszewski, Grzegorz
Zwolińska, Paulina
Sulkowska, Ewa
Łętowska, Magdalena
Kubicka-Russel, Dorota
Chrzanowska, Anna
Noceń, Ewa
AuthorAffiliation 2 Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; mletowska@ihit.waw.pl
1 Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; drussel@ihit.waw.pl (D.K.-R.); gliszewski@ihit.waw.pl (G.L.); esulkowska@ihit.waw.pl (E.S.); achrzanowska@ihit.waw.pl (A.C.); pzwolinska@ihit.waw.pl (P.Z.); enocen@ihit.waw.pl (E.N.); apotepa@ihit.waw.pl (A.P.); pgrabarczyk@ihit.waw.pl (P.G.)
AuthorAffiliation_xml – name: 1 Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; drussel@ihit.waw.pl (D.K.-R.); gliszewski@ihit.waw.pl (G.L.); esulkowska@ihit.waw.pl (E.S.); achrzanowska@ihit.waw.pl (A.C.); pzwolinska@ihit.waw.pl (P.Z.); enocen@ihit.waw.pl (E.N.); apotepa@ihit.waw.pl (A.P.); pgrabarczyk@ihit.waw.pl (P.G.)
– name: 2 Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland; mletowska@ihit.waw.pl
Author_xml – sequence: 1
  givenname: Aneta
  surname: Kopacz
  fullname: Kopacz, Aneta
– sequence: 2
  givenname: Dorota
  surname: Kubicka-Russel
  fullname: Kubicka-Russel, Dorota
– sequence: 3
  givenname: Grzegorz
  surname: Liszewski
  fullname: Liszewski, Grzegorz
– sequence: 4
  givenname: Ewa
  surname: Sulkowska
  fullname: Sulkowska, Ewa
– sequence: 5
  givenname: Anna
  surname: Chrzanowska
  fullname: Chrzanowska, Anna
– sequence: 6
  givenname: Paulina
  surname: Zwolińska
  fullname: Zwolińska, Paulina
– sequence: 7
  givenname: Ewa
  surname: Noceń
  fullname: Noceń, Ewa
– sequence: 8
  givenname: Anna
  surname: Potępa
  fullname: Potępa, Anna
– sequence: 9
  givenname: Magdalena
  surname: Łętowska
  fullname: Łętowska, Magdalena
– sequence: 10
  givenname: Piotr
  surname: Grabarczyk
  fullname: Grabarczyk, Piotr
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39861849$$D View this record in MEDLINE/PubMed
BookMark eNptkstuEzEUhi1URNvAghdAI7GBRYpvY49XqA2FRqpEJSq2lsdzZuJoYgd7Uqm7vgPseLs-CU7ShgYhL2z9_vyfi88xOvDBA0KvCT5hTOEPN0RigrHAz9ARUUqNuSLlwZPzITpOaZ4JobB8gQ6ZqgSpuDpCvy9gaQY3uFScFd9dXKXC-eIq9C7NirM-hKb4FHyIG3mYQXEF0WWRYlze3_2kmKj7u1_fXOdd66zxQzGZGd_Bhj9fugYWLvShuy2Mz1awCF00y5mzay4aO2S7NDibitAWU99CVh5DvkTPW9MnePWwj9D15_PrycX48uuX6eT0cmy5ksO4UYRhbKlqoJbABJFM1ERgIzETwGTdUE5LxUTTVIaDtQRaqyTwlhhKSzZC061tE8xcL6NbmHirg3F6I4TYaRNzij1ozDmX-aWhXPJ63UVT4xy9VgoTWtrs9XHrtVzVC2gs-CGafs90_8a7me7CjSZEiqrKGY_QuweHGH6sIA164ZKFvjcewippRkpVYb5N_O0_6Dysos-t2lC5EYLhv1RncgXOtyEHtmtTfVoxKjkTtMrUyX-ovNYfaPO4tS7rew_ePK10V-LjaGXg_RawMaQUod0hBOv12Ord2LI_k8zdrQ
Cites_doi 10.1111/trf.16559
10.1111/vox.12890
10.32394/pe.72.4.19
10.1200/JCO.2008.18.0182
10.1016/j.vaccine.2005.08.058
10.7326/M15-1121
10.1111/trf.16675
10.1186/s12879-024-09753-8
10.1111/j.1440-1746.2009.06165.x
10.1016/j.jhep.2015.01.018
10.3390/v14112507
10.1111/trf.16431
10.1016/j.achaem.2017.07.006
10.1093/pubmed/fdx189
10.1016/j.tmrv.2020.02.001
10.1016/j.jhep.2019.03.034
10.1371/journal.pone.0246704
10.1016/S1386-6532(05)00384-7
10.32394/pe.75.34
10.5603/JTM.2023.0005
10.1093/infdis/jiw142
10.5603/JTM.2021.0005
10.3390/v14122611
10.1002/hep.29022
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
CorporateAuthor the Group of Polish Blood Transfusion Centers for Blood Borne Pathogens
CorporateAuthor_xml – name: the Group of Polish Blood Transfusion Centers for Blood Borne Pathogens
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7U9
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/v17010060
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database


MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1999-4915
ExternalDocumentID oai_doaj_org_article_044477e4a2474b3986ab0130b990125c
PMC11768870
A832743628
39861849
10_3390_v17010060
Genre Journal Article
GeographicLocations Poland
France
United States--US
Europe
Germany
GeographicLocations_xml – name: Poland
– name: Germany
– name: United States--US
– name: France
– name: Europe
GroupedDBID ---
2WC
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACUHS
AFKRA
AFPKN
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
DIK
E3Z
EBD
ESX
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M48
M7P
MODMG
M~E
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
TR2
TUS
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
PMFND
3V.
7U9
7XB
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c497t-d91300c29deb7e361736b160a7036e37bd2425936dd8a4ecc1efc97e4f1a2253
IEDL.DBID M48
ISSN 1999-4915
IngestDate Wed Aug 27 01:16:54 EDT 2025
Thu Aug 21 18:40:36 EDT 2025
Fri Jul 11 06:07:42 EDT 2025
Sat Aug 23 14:08:54 EDT 2025
Tue Jun 17 21:57:02 EDT 2025
Tue Jun 10 20:58:39 EDT 2025
Mon Jul 21 05:31:57 EDT 2025
Tue Jul 01 01:53:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords prevalence
HBV
incidence
blood donor
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c497t-d91300c29deb7e361736b160a7036e37bd2425936dd8a4ecc1efc97e4f1a2253
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Group of Polish Blood Transfusion Centers for Blood Borne Pathogens authors are listed in the Acknowledgments.
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/v17010060
PMID 39861849
PQID 3159617630
PQPubID 2032319
ParticipantIDs doaj_primary_oai_doaj_org_article_044477e4a2474b3986ab0130b990125c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11768870
proquest_miscellaneous_3159804225
proquest_journals_3159617630
gale_infotracmisc_A832743628
gale_infotracacademiconefile_A832743628
pubmed_primary_39861849
crossref_primary_10_3390_v17010060
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-01-01
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – month: 01
  year: 2025
  text: 2025-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Viruses
PublicationTitleAlternate Viruses
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Yeo (ref_31) 2009; 27
Sonali (ref_32) 2016; 164
Magdzik (ref_11) 2006; 60
ref_14
Kopacz (ref_15) 2023; 16
ref_36
Stepien (ref_29) 2012; 66
Madalinski (ref_4) 2015; 69
ref_10
Koc (ref_24) 2021; 61
Velati (ref_25) 2019; 17
Grabarczyk (ref_38) 2017; 48
Locarnini (ref_6) 2015; 62
Chen (ref_7) 2010; 25
Kopacz (ref_16) 2021; 14
ref_17
ref_37
Stepien (ref_27) 2018; 72
Raimondo (ref_35) 2019; 71
Simons (ref_5) 2016; 214
Seto (ref_33) 2017; 65
Vermeulen (ref_18) 2021; 61
Kowalczyk (ref_12) 2021; 75
Ye (ref_30) 2017; 15
Lavanchy (ref_2) 2005; 34
Bauer (ref_3) 2006; 24
ref_22
ref_20
Lelie (ref_34) 2021; 61
ref_1
Xu (ref_19) 2019; 41
Rosinska (ref_28) 2009; 63
Scheiblauer (ref_23) 2020; 115
ref_9
ref_8
Grabarczyk (ref_13) 2009; 1
Dodd (ref_26) 2020; 34
Alvarez (ref_21) 2019; 17
References_xml – volume: 61
  start-page: 2688
  year: 2021
  ident: ref_18
  article-title: An assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safety
  publication-title: Transfusion
  doi: 10.1111/trf.16559
– volume: 115
  start-page: 152
  year: 2020
  ident: ref_23
  article-title: Detection of hepatitis B virus infection in German blood donors 2008–2015
  publication-title: Vox Sang.
  doi: 10.1111/vox.12890
– ident: ref_9
– volume: 72
  start-page: 441
  year: 2018
  ident: ref_27
  article-title: Hepatitis B in Poland in 2016
  publication-title: Przegl. Epidemiol.
  doi: 10.32394/pe.72.4.19
– volume: 15
  start-page: 6
  year: 2017
  ident: ref_30
  article-title: Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China
  publication-title: Blood Transfus.
– volume: 27
  start-page: 605
  year: 2009
  ident: ref_31
  article-title: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.18.0182
– volume: 24
  start-page: 572
  year: 2006
  ident: ref_3
  article-title: Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.08.058
– volume: 164
  start-page: 30
  year: 2016
  ident: ref_32
  article-title: Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: A systematic review and meta-analysis
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M15-1121
– volume: 60
  start-page: 471
  year: 2006
  ident: ref_11
  article-title: Epidemiological situation of hepatitis B in Poland in the years 1979–2004
  publication-title: Przegl. Epidemiol.
– volume: 61
  start-page: 3190
  year: 2021
  ident: ref_34
  article-title: Residual risk of transfusion-transmitted hepatitis B virus (TT-HBV) infection by NAT-screened blood components: A review of observed versus modeled infectivity from donors with window period and occult HBV infections
  publication-title: Transfusion
  doi: 10.1111/trf.16675
– volume: 69
  start-page: 47
  year: 2015
  ident: ref_4
  article-title: Current views on the persistence of immunity following hepatitis B vaccination
  publication-title: Przegl. Epidemiol.
– ident: ref_37
– ident: ref_14
– volume: 17
  start-page: 418
  year: 2019
  ident: ref_21
  article-title: Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003–2017)
  publication-title: Blood Transfus.
– ident: ref_1
– ident: ref_36
  doi: 10.1186/s12879-024-09753-8
– volume: 25
  start-page: 19
  year: 2010
  ident: ref_7
  article-title: Toward elimination and eradication of hepatitis B
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/j.1440-1746.2009.06165.x
– volume: 63
  start-page: 245
  year: 2009
  ident: ref_28
  article-title: Hepatitis B in Poland in 2007
  publication-title: Przeg.L Epidemiol.
– volume: 62
  start-page: 76
  year: 2015
  ident: ref_6
  article-title: Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2015.01.018
– ident: ref_8
– ident: ref_22
  doi: 10.3390/v14112507
– volume: 61
  start-page: 2125
  year: 2021
  ident: ref_24
  article-title: Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of universal vaccination and migration
  publication-title: Transfusion
  doi: 10.1111/trf.16431
– volume: 48
  start-page: 174
  year: 2017
  ident: ref_38
  article-title: Risk of transmission of blood-derived pathogens by transfusion in Poland
  publication-title: Acta Haematol. Pol.
  doi: 10.1016/j.achaem.2017.07.006
– volume: 66
  start-page: 277
  year: 2012
  ident: ref_29
  article-title: Hepatitis B in Poland in 2010
  publication-title: Przegl. Epidemiol.
– volume: 1
  start-page: 20
  year: 2009
  ident: ref_13
  article-title: Wykrywanie HBsAg u polskich dawców krwi w latach 1995–2004
  publication-title: J. Transf. Med.
– volume: 41
  start-page: 55
  year: 2019
  ident: ref_19
  article-title: Prevalence and trends of transfusion-transmittable infections among blood donors in Southwest China
  publication-title: J. Public Health
  doi: 10.1093/pubmed/fdx189
– volume: 34
  start-page: 81
  year: 2020
  ident: ref_26
  article-title: Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016
  publication-title: Transfus. Med. Rev.
  doi: 10.1016/j.tmrv.2020.02.001
– volume: 71
  start-page: 397
  year: 2019
  ident: ref_35
  article-title: Update of the statements on biology and clinical impact of occult hepatitis B virus infection
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2019.03.034
– ident: ref_10
– ident: ref_17
  doi: 10.1371/journal.pone.0246704
– volume: 34
  start-page: 1
  year: 2005
  ident: ref_2
  article-title: Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention
  publication-title: J. Clin. Virol.
  doi: 10.1016/S1386-6532(05)00384-7
– volume: 17
  start-page: 409
  year: 2019
  ident: ref_25
  article-title: Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018
  publication-title: Blood Transfus.
– volume: 75
  start-page: 367
  year: 2021
  ident: ref_12
  article-title: Hepatitis B in Poland in 2019
  publication-title: Przegl. Epidemiol.
  doi: 10.32394/pe.75.34
– volume: 16
  start-page: 39
  year: 2023
  ident: ref_15
  article-title: Demographic changes in the Polish blood donors eligible for blood donation and screened for transfusion-transmitted infections (2005–2018)
  publication-title: J. Transf. Med.
  doi: 10.5603/JTM.2023.0005
– volume: 214
  start-page: 273
  year: 2016
  ident: ref_5
  article-title: A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiw142
– volume: 14
  start-page: 73
  year: 2021
  ident: ref_16
  article-title: Strategies for hepatitis B virus screening of Polish blood donors (2005–2020)
  publication-title: J. Transf. Med.
  doi: 10.5603/JTM.2021.0005
– ident: ref_20
  doi: 10.3390/v14122611
– volume: 65
  start-page: 1451
  year: 2017
  ident: ref_33
  article-title: Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study
  publication-title: Hepatology
  doi: 10.1002/hep.29022
SSID ssj0066907
Score 2.391112
Snippet In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/105 inhabitants). Pursuant to the WHO...
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10 inhabitants). Pursuant to the WHO...
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10[sup.5] inhabitants). Pursuant to the WHO...
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10 5 inhabitants). Pursuant to the WHO...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 60
SubjectTerms Adolescent
Adult
Age
Blood & organ donations
blood donor
Blood donors
Blood Donors - statistics & numerical data
Blood transfusion
Demographic aspects
DNA, Viral - blood
Enzymes
Epidemiology
Female
HBV
Health aspects
Hepatitis B
Hepatitis B - blood
Hepatitis B - epidemiology
Hepatitis B - virology
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B virus - immunology
Hepatitis B virus - isolation & purification
Humans
Hypothesis testing
Immunization
Incidence
Male
Middle Aged
Neonates
Poland - epidemiology
prevalence
Prophylaxis
Seroepidemiologic Studies
Vaccination
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hSkhcEOUZKMggJE5Rkzhx4mMXWi1IICQK6s2yHZvmgIP2Uam3_ge48e_6S5iJs8tGHLhwtSeJ7RnPwxl_A_DSNsJb1HopehMiLfPCpKZsTOq9b43mvJYV3UZ-_0HMP5fvzqqznVJflBMW4YHjwh0Snlldu1IXZV0aLhuh6eguM_RDp6gsaV-0eZtgKupgQTFfxBHiGNQfXhDqOEGPTKzPANL_tyresUXTPMkdw3NyB26PHiM7iiPdhxsu3IWbsYbk5T34NXeUFL3qlmzGvnSL9ZJ1gVFa2_KczSgtnb3pQ78YmtHbYx9R5rCRznmur36gZZbXVz8_dV8DJQ3hOrN44WCgP_5TP_aS6YCvct8ixnVniW4X65n1nr0dUrvc5pP34fTk-PT1PB0rLqS2lPUqbSX93bKFbJ2pHUfvhguTi0wTTJfjtWkpQpFctG2jS-R-7ryVyB2fa1QM_AHshT64R8B8Xbiscd7kHEM247SpMovyUvFMowDkCbzYMEJ9j7gaCuMR4pbaciuBGbFoS0BQ2EMDCogaBUT9S0ASeEUMVrRhkYtWj_cOcJwEfaWOUKehGyWKJoGDCSVuNDvt3oiIGjf6UnF0B3GZBMfBPt9205OUvBZcv440DWGtVQk8jBK1nRKNF4NsmUAzkbXJnKc9oTsfYMBz_CyaiOzx_1ilJ3CroMrGw-HSAeytFmv3FN2tlXk27KzfTW0oDQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwEB5BERIXxD8pBRmExClqEid2ckJdaLUggZAoaG-R7dhtDiRls1upt74D3Hi7PgkzTjbdCImrPbtxMn-e8fgbgNcmF86g1QtxNyHCNE50qNNch865SivOZZHRbeRPn8X8W_pxkS2GhFs3lFVubKI31FVrKEe-z9HvorcVPHp79jOkrlF0ujq00LgJtwi6jKRaLsaAS1Dk16MJcQzt988Je5wASCY-yEP1_2uQtzzStFpyy_0c3YO7w76RHfSMvg83bPMAbvedJC8ewp-5pdLoVd2xGfteL9cdqxtGxW3dKZtRcTp73zbt0g_jno99QcnDQcr2XF3-Qv9cXF3-_lqfNFQ6hF-b9dcOPP3hdRfZC6Ya_Cv7o0e6rg3RbSM-s9axD77Ay24e-QiOjw6P383Doe9CaNJCrsKqoDMukxSV1dJy_Opc6FhEisC6LJe6ojil4KKqcpWiDMTWmULa1MUKzQN_DDtN29inwJxMbJRbp2OOgZu2SmeRQanJeKRQDOIAXm0YUZ716BolRiXErXLkVgAzYtFIQIDYfqBdnpSDfpUEeydxCSpJZap5kQtFGd5I07lfkpkA3hCDS1Jb5KJRw-0DXCcBYJUHaNlwMyWSPIC9CSWqm5lOb0SkHNS9K6-FM4CX4zT9kkrYGtuue5qcENeyAJ70EjW-Eq0XQ-0igHwia5N3ns409akHA4_xsegoot3_r-sZ3Emoc7FPHu3Bzmq5ts9xO7XSL7zO_AVlKyFt
  priority: 102
  providerName: ProQuest
Title Hepatitis B Virus in Polish Blood Donors in the Period 2005–2019—Significant Changes in Epidemiology and Demographic Characteristics of Infected Donors
URI https://www.ncbi.nlm.nih.gov/pubmed/39861849
https://www.proquest.com/docview/3159617630
https://www.proquest.com/docview/3159804225
https://pubmed.ncbi.nlm.nih.gov/PMC11768870
https://doaj.org/article/044477e4a2474b3986ab0130b990125c
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB71ISQuiDeBsjIIiVMgiRM7OSDUhS0LUqsKWrS3yHacNhIkkN1F7K3_AW78u_4SZvJYNoIDlxzsSWJ7xp4Ze_wNwBMTi9zgqueiNSHc0A-0q8NYu3meZ1pxLpOIbiMfHonpafhuFs22oM-x2Q3g_J-uHeWTOq0_Pfv-dfUSJ_wL8jjRZX_-jTDFCVhkG3ZRIUlKZHAYrg8TBDmAzeFyQgnV_KgFGBq-OlBLDXr_32v0hpIaBlBuaKSD63CtMyXZfsv7G7Bly5twpU0uuboFv6aWoqUXxZyN2ceiXs5ZUTKKd5ufszHFq7PXVVnVTTGagewYhRELaQPo8uIHquzk8uLnh-KspGgiZABrbyI09JM_iWVXTJX4Kfu5Bb8uDNFtgkCzKmdvm5gv2__yNpwcTE5eTd0uFYNrwkQu3CyhYy8TJJnV0nI0e7jQvvAU4XdZLnVGrkvCRZbFKkSx8G1uEmnD3Fe4YvA7sFNWpb0HLJeB9WKba5-jL6et0pFnUJAi7imUDN-Bxz0j0i8t4EaKjgpxK11zy4ExsWhNQBjZTUFVn6XdlEsJCU9iE1QQylDzJBaKNn09TUeBQWQceEoMTkm2kItGdRcSsJ2EiZXu42KH9pUIYgf2BpQ4A82wuheRtBfglKOdiMMkODb20bqa3qSottJWy5YmJhC2yIG7rUStu0TtRe87cSAeyNqgz8Oasjhv8MF9_C3qDu_-f3fwAVwNKK9xs7W0BzuLemkforG10CPYljM5gt3x5Oj4_ajZssDnm5k_aibZb4fiLUA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFH4qRQguiLUEChgE4hQ1ibMeEOrQVjN0ERIDmptlO06bA0mZBTS3_gd662_gT_WX8F62ToTErVfbcWy93X7-HsAbHYeZRq1nozcR2r7rKVv5sbKzLEuV5DxKAnqNfHgUDr_6nybBZA3-tG9hKK2y1YmVok5LTWfkWxztLlrbkDsfTn_YVDWKblfbEho1W-yb5S8M2WbvRztI37eet7c7_ji0m6oCtvaTaG6nCd3gaC9JjYoMxzl5qNzQkQRFZXikUvLCEx6maSx93KFrMp1Exs9ciczPcdobcBPtrkOxXjTp4ruQAs0avIjzxNn6SVDnhHfSM3lVZYB_9f-KAewnZ65Yu717cLdxU9l2zVf3Yc0UD-BWXbhy-RAuhoYysef5jA3Yt3y6mLG8YJRLNzthA8qFZztlUU6rZnQx2WdkdGykw6XLs9_oDiSXZ-df8uOCMpWQuKx-5VCN370qWrtkssCpzPcaWDvXNG4VYJqVGRtV-WSm_eUjGF8HQR7DelEW5gmwLPKME5tMuRzjRGWkChyNTBpwRyLXuRa8bgkhTmswD4FBEFFLdNSyYEAk6gYQ_nbVUE6PRSPOglD2IlyC9PzIVzyJQ0kHyo6ia0Yv0Ba8IwIL0hJIRS2bxw64TsLbEtuoSNF3C73Ygs3eSJRu3e9uWUQ02mUmrmTBglddN31JGXOFKRf1mJgA3gILNmqO6rZE68XIPrEg7vFab8_9niI_qbDHXfwt2iXn6f_X9RJuD8eHB-JgdLT_DO54VDS5OrfahPX5dGGeoyc3Vy8q-WEgrlle_wKafV0-
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwEB4tXYG4IN4EFjAIxClqEud5QGhLW7UsVBUsaG9W7Di7OZAsTQvqbf8D3Pgl_J39Jczk0W2ExG2vtuPYmrc9_gbghQr9VKHWM9Gb8E3XdqQp3VCaaZomMuY8iDx6jfxh5k8-u--OvKMd-NO-haG0ylYnVoo6KRSdkfc52l20tj63-mmTFjEfjt-cfjOpghTdtLblNGoWOdDrHxi-la-nQ6T1S8cZjw7fTsymwoCp3ChYmklEtznKiRItA81xfu5L27digqXSPJAJeeQR95MkjF3cra1TFQXaTe0YBYHjtFdgN6CgqAe7g9Fs_rE1Az6FnTWUEeeR1f9OwOeEftIxgFWdgH-twZY57KZqbtm-8U240TitbL_msluwo_PbcLUuY7m-A78nmvKyl1nJBuxLtliVLMsZZdaVJ2xAmfFsWOTFompGh5PNke2xkY6azs9-onMQnZ_9-pQd55S3hKRm9ZuHavzoooTtmsU5TqW_1jDbmaJx23DTrEjZtMou0-0v78LhZZDkHvTyItcPgKWBo61Qp9LmGDVKHUvPUsiyHrdi5EHbgOctIcRpDe0hMCQiaokNtQwYEIk2AwiNu2ooFseiEW5BmHsBLiF23MCVPAr9mI6XLUmXjo6nDHhFBBakM5CKKm6ePuA6CX1L7KNaRU_Od0ID9jojUdZVt7tlEdHomlJcSIYBzzbd9CXlz-W6WNVjQoJ78wy4X3PUZku0XozzIwPCDq919tztybOTConcxt-ilbIe_n9dT-Eayqp4P50dPILrDlVQrg6x9qC3XKz0Y3TrlvJJI0AMxCWL7F-1m2LZ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatitis+B+Virus+in+Polish+Blood+Donors+in+the+Period+2005%E2%80%932019%E2%80%94Significant+Changes+in+Epidemiology+and+Demographic+Characteristics+of+Infected+Donors&rft.jtitle=Viruses&rft.au=Kopacz%2C+Aneta&rft.au=Kubicka-Russel%2C+Dorota&rft.au=Liszewski%2C+Grzegorz&rft.au=Sulkowska%2C+Ewa&rft.date=2025-01-01&rft.pub=MDPI+AG&rft.issn=1999-4915&rft.eissn=1999-4915&rft.volume=17&rft.issue=1&rft_id=info:doi/10.3390%2Fv17010060&rft.externalDocID=A832743628
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon